Metabolic Syndrome Target

What is Metabolic Syndrome?

Metabolic syndrome is an aggregate of conditions that collectively elevate the risk of cardiovascular disease, stroke, and diabetes. Key components include elevated blood pressure, increased blood sugar levels, excessive abdominal fat, and abnormal cholesterol or triglyceride levels. This syndrome is often associated with obesity, sedentariness, and insulin resistance, forming a significant research focus due to its rising prevalence globally.

Exploring Therapeutic Strategies by Mechanism of Action (MOA)

For researchers delving into the pathophysiology of metabolic syndrome, each component is underpinned by distinct mechanisms of action (MOA) that may serve as potential targets for therapeutic intervention or biomarkers for diagnosis and progression monitoring.

  • Insulin Resistance (MOA)

    • Key in metabolic syndrome, insulin resistance is a pivotal research area for understanding the development of prediabetes and type 2 diabetes.

  • Obesity-Related Inflammation (MOA)

    • Visceral adiposity contributes to systemic inflammation, offering a research avenue into metabolic dysfunction interventions.

  • Dyslipidemia (MOA)

    • Aberrations in lipid metabolism, characterized by high LDL cholesterol and low HDL cholesterol, are crucial in atherosclerosis research.

  • Hypertension (MOA)

    • Investigating the interplay between obesity, insulin resistance, and blood pressure elevation is essential for cardiovascular risk reduction strategies.

  • Endothelial Dysfunction (MOA)

    • A primary event in atherogenesis, endothelial dysfunction's role in metabolic syndrome is a promising research domain for cardiovascular prevention.


Detailed Insights into Therapeutic and Diagnostic Targets of MOA-Based Strategies

Metabolic syndrome represents a critical focus for researchers investigating the intersection of lifestyle factors, genetic predisposition, and chronic disease development. By elucidating the underlying mechanisms of action (MOAs) for each component of metabolic syndrome, research can guide the development of targeted therapies and precise diagnostic tools. The table below, crafted for a research-oriented audience, presents an integrated view of therapeutic targets and diagnostic markers for metabolic syndrome

MOA Target/Biomarker Target ID Therapeutic Use Diagnostic Use
Insulin Resistance Insulin Receptor (INSR) GM-T85435 Metformin (indirectly affects INSR to improve insulin sensitivity) Clinical assessment rather than direct biomarker measurement.
Obesity-Related Inflammation Tumor Necrosis Factor-alpha (TNF-α) GM-T20178 Lifestyle changes; TNF-α inhibitors for related inflammation Elevated TNF-α levels (indicator of inflammation)
Dyslipidemia Apolipoprotein B (ApoB) GM-T07533 Statins (lower LDL cholesterol by inhibiting HMG-CoA reductase) ApoB levels (assess LDL particle number and cardiovascular risk)
Cholesterol ester transfer protein (CETP) GM-T15334 CETP inhibitors (investigated for raising HDL cholesterol levels) Not directly used in diagnostics
Hypertension Angiotensin-converting enzyme (ACE) GM-T82577 ACE inhibitors (reduce blood pressure by inhibiting angiotensin II production) Plasma renin activity and serum aldosterone (not ACE levels directly)
Endothelial Dysfunction Endothelial Nitric Oxide Synthase (eNOS) GM-T06046 L-arginine supplementation; lifestyle changes (enhance endothelial function) Flow-mediated dilation (endothelial function assessment)


Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy